We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zoetis (ZTS) Suffers a Larger Drop Than the General Market: Key Insights
Read MoreHide Full Article
Zoetis (ZTS - Free Report) ended the recent trading session at $76.09, demonstrating a -2.22% change from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 0.05%. Elsewhere, the Dow saw a downswing of 0.09%, while the tech-heavy Nasdaq depreciated by 0.24%.
Shares of the animal health company witnessed a loss of 0.57% over the previous month, trailing the performance of the Medical sector with its gain of 4.42%, and outperforming the S&P 500's loss of 1.42%.
The investment community will be paying close attention to the earnings performance of Zoetis in its upcoming release. The company is slated to reveal its earnings on August 6, 2026. The company is expected to report EPS of $1.85, up 5.11% from the prior-year quarter. Meanwhile, the latest consensus estimate predicts the revenue to be $2.49 billion, indicating a 1.39% increase compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates project earnings of $6.91 per share and a revenue of $9.75 billion, demonstrating changes of +7.8% and +2.96%, respectively, from the preceding year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Zoetis. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.13% higher. Currently, Zoetis is carrying a Zacks Rank of #4 (Sell).
In terms of valuation, Zoetis is currently trading at a Forward P/E ratio of 11.26. This indicates a discount in contrast to its industry's Forward P/E of 17.02.
Meanwhile, ZTS's PEG ratio is currently 1.21. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The average PEG ratio for the Medical - Drugs industry stood at 1.69 at the close of the market yesterday.
The Medical - Drugs industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 103, finds itself in the top 43% echelons of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Zoetis (ZTS) Suffers a Larger Drop Than the General Market: Key Insights
Zoetis (ZTS - Free Report) ended the recent trading session at $76.09, demonstrating a -2.22% change from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 0.05%. Elsewhere, the Dow saw a downswing of 0.09%, while the tech-heavy Nasdaq depreciated by 0.24%.
Shares of the animal health company witnessed a loss of 0.57% over the previous month, trailing the performance of the Medical sector with its gain of 4.42%, and outperforming the S&P 500's loss of 1.42%.
The investment community will be paying close attention to the earnings performance of Zoetis in its upcoming release. The company is slated to reveal its earnings on August 6, 2026. The company is expected to report EPS of $1.85, up 5.11% from the prior-year quarter. Meanwhile, the latest consensus estimate predicts the revenue to be $2.49 billion, indicating a 1.39% increase compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates project earnings of $6.91 per share and a revenue of $9.75 billion, demonstrating changes of +7.8% and +2.96%, respectively, from the preceding year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Zoetis. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.13% higher. Currently, Zoetis is carrying a Zacks Rank of #4 (Sell).
In terms of valuation, Zoetis is currently trading at a Forward P/E ratio of 11.26. This indicates a discount in contrast to its industry's Forward P/E of 17.02.
Meanwhile, ZTS's PEG ratio is currently 1.21. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The average PEG ratio for the Medical - Drugs industry stood at 1.69 at the close of the market yesterday.
The Medical - Drugs industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 103, finds itself in the top 43% echelons of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.